Clincosm LogoSign in Get a demo

regorafenib

Showing 1 - 6 of 6
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

TAS-102 in Combination With Regorafenib or Fruquintinib for

Not yet recruiting
  • TAS 102
  • +3 more
  • (no location specified)
Aug 7, 2023

Hepatocellular Carcinoma, Transcatheter Arterial ChEmoembolization, Regorafenib Trial in Guangzhou (TACE, Regorafenib)

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    FirstSunYetSen
Apr 12, 2023

Colorectal Cancer Liver Metastases, Regorafenib Trial in Guangdong (Regorafenib and DIBIRI, Regorafenib)

Recruiting
  • Colorectal Cancer Liver Metastases
  • Regorafenib
  • Guangdong, Guangzhou, China
    Bo Zhang
Mar 20, 2023

Regorafenib, Raltitrexed, Colorectal Tumors Trial (Regorafenib, Raltitrexed)

Not yet recruiting
  • Regorafenib
  • +3 more
  • (no location specified)
Jun 24, 2022

Hepatocellular Carcinoma, Regorafenib, PD-1 Inhibitor Trial in Beijing (Regorafenib, PD-1 inhibitor)

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Beijing, Beijing, China
    Hai-Tao Zhao
Sep 15, 2021

cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1

Not yet recruiting
  • HCC
  • +3 more
  • (no location specified)
Aug 28, 2021